Inhibitors of phosphodiesterase type 5 (PDE-5) are well established as an oral treatment for the majority of patients with erectile dysfunction (ED). PDE-5 is found in high concentration in smooth muscle cells of the corpora cavernosa. However, enzymes of the PDE family are also expressed in various other tissues, including the brain. Little is known about its effects on the central nervous system (CNS), although it has been suggested that PDE-5 inhibitors might cross the blood-brain barrier. Side effects, such as headache, nasal congestion, flushing, nausea, are much more common. We describe a patient who had a transient global amnesia (TGA) after his first-ever use of tadalafil, a potent PDE-5 inhibitor. Despite the fact that the aetiology of TGA has not entirely been clarified at present, we consider the hypothesis of a causal relationship as tempting with respect to the current hypotheses of TGA pathophysiology. This case, together with others, suggests that PDE-5 inhibitors might be capable of exerting adverse effects in the CNS. Physicians should be aware of the possibility of neurological disturbances when prescribing PDE-5 inhibitors for ED.
Introduction
In late 2003, two new phosphodiesterase type 5 (PDE-5) inhibitors-tadalafil (Cialis; Lilly) and vardenafil (Levitra; Bayer/GlaxoSmithKline)-were approved by the US Food and Drug Administration for the treatment of erectile dysfunction (ED). Tadalafil is a potent PDE-5 inhibitor with an extended half-life compared to sildenafil (Viagra; Pfizer), the first PDE-5 inhibitor approved for ED and the most widely prescribed PDE-5 inhibitor. 1 There are well-known risks of cardiac complications in patients taking PDE-5 inhibitors together with organic nitrates. However, the pharmacological basis of neurological symptoms associated with the use of PDE-5 inhibitors is poorly understood, even though PDE-5 is expressed to high degree in some regions of the brain. Some authors have suggested that there is an increased risk of cerebrovascular events in association with sildenafil. [2] [3] [4] Others reported two cases of tonic-clonic seizures after sildenafil. 5 Transient global amnesia (TGA), which occurred soon after the intake of sildenafil, has been published previously in three patients. 6, 7 TGA is a benign clinical entity of unknown aetiology. It is characterised by the abrupt onset of severe anterograde amnesia, which lasts less than 24 h and is not associated with other focal neurological symptoms. We describe a patient who had a transient event of global amnesia after his firstever use of tadalafil. This case suggests that PDE-5 inhibitors might, in general, be capable of exerting adverse effects in the central nervous system (CNS).
Case report
A 46-year-old man was brought by his girlfriend to our emergency room because of memory impairment since the time they both woke up in the morning. He could not remember any of the events of that day or of the previous night. He could not even remember that he had returned from a sailing trip the night before and that they had sexual intercourse. He repeatedly asked his girlfriend 'What is wrong with me?'. She had found a blister with two tadalafil pills (2 Â 20 mg), of which one was missing. Although the patient did not remember taking the tadalafil, he did remember that the pills belonged to him. His medical history was unremarkable. He was found to have a blood pressure of 130/75 and a body mass index of 26.4. Body temperature and routine blood tests were in the normal range. Cardiovascular examination was normal. During the neurological examination, he repeatedly asked what had happened to him and was unable to retain answers to his questions. He was alert but recalled only one of five items at 1 and 5 min. Long-term memory was preserved and no further abnormalities were found. Results of a cranial CT scan were normal. During the next hours, his memory gradually improved. He was discharged 12 h later with a persistent residual amnesia for the period of the attack and retrograde amnesia for events that occurred the night before. He was advised to abstain from tadalafil use.
Discussion
The clinical characteristics of the reported case fulfilled the widely accepted TGA criteria of Hodges and Warlow. 8 This is the first report of TGA occurring soon after the first-ever assumption of tadalafil. TGA is, in general, a rare condition with an estimated incidence of 5-9/100 000 per year. 9 However, there have been 35 reports of amnesia as a symptom among 274 adverse event reports between January 1998 and February 2001, which designated sildenafil as the primary suspect of various neurological disturbances.
10 PDE-5 inhibitors interact pharmacologically with nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signalling pathways. The cGMP accumulates, causing smooth muscle relaxation and increased blood flow into the corpus cavernosum. Since PDE-5 is found in the brain as well as in the corpus cavernosum, tadalafil and other PDE-5 inhibitors might exert side effects in the CNS by crossing the blood-brain barrier. 11, 12 There are several hypotheses concerning the aetiology of TGA. Lewis proposed that an increased central venous return during Valsalva-like manoeuvres may cause hippocampal oligaemia due to venous congestion. 13 Indeed, PDE-5 inhibitors are well known to have several vasodilating side effects such as flushing, dizziness, vasodilatory headache, hyperaemic nasal congestion, nose bleeding and changes in pulmonary blood flow. 1 It could be assumed that their vasodilatory effect is not only confined to the corpus cavernosum and that it may trigger a TGA attack in conjunction with sexual intercourse. However, another favoured mechanism that has been claimed to be responsible for TGA is a migraineous disturbance of brain function, causing cortical spreading depression (CSD). CSD is a propagating wave of neuronal and glial depolarisation, leading to a transient disruption of local ionic homeostasis. Since it has been claimed that NO plays a crucial role in its pathophysiology, PDE-5 inhibitors might precipitate CSD in hippocampal regions by their interaction with intracellular NOcGMP signalling pathways.
In conclusion, the hypothesis of a connection between PDE-5 inhibitors and TGA is tempting with respect to the above hypotheses of TGA pathophysiology. We cannot rule out the possibility of coincidence or that sexual intercourse was the only precipitating factor. However, the fact that TGA occurred soon after the patient's first-ever use of a PDE-5 inhibitor in our case as well as in other cases may argue for a causal link. 6 Physicians should be aware of the possibility of neurological disturbances when prescribing PDE-5 inhibitors for ED. Since migraine is a risk factor for TGA, it has been proposed that these drugs should also be used with caution in patients with a history of migraine.
